Eli Lilly's Trulicity beats growth expectations

Just like Novo Nordisk, Eli Lilly has demonstrated that diabetes drugs sell well.

Photo: Mike Blake/REUTERS / X00030

Novo Nordisk’s big US-based competitor, Eli Lilly, has exceeded the sales expectations of its leading diabetes type 2 drug, just as its Danish counterpart could announce the same thing in its financial report on Wednesday.

Sales of the GLP 1 drug Trulicity, which is in direct competition with Novo Nordisk’s Ozempic and its predecessor Victoza, grew by 25 percent to USD 1.9bn in the fourth quarter of 2021, the company’s full-year financial figures show on Thursday. Analysts asked by Bloomberg only predicted an increase to USD 1.78bn prior to the report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs